Tissue pathway factor inhibitor (TFPI) activity is elevated in pregnant patients at 20 weeks gestation who subsequently develop preeclampsia

Sarah Hillman; Ian Chant; Mei Gu; Peter Rose; Manu Vatish

doi:10.1160/TH08-10-0633

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2009; 101(04): 778-780
DOI: 10.1160/TH08-10-0633

Letters to the Editor

Schattauer GmbH

Tissue pathway factor inhibitor (TFPI) activity is elevated in pregnant patients at 20 weeks gestation who subsequently develop preeclampsia

Sarah Hillman

¹Clinical Science and Research Institute, Warwick University, Clifford Bridge Road, Coventry, UK

³University Hospital of Coventry, Clifford Bridge Road, Coventry, UK

,

Ian Chant

²Warwick General Hospital Haematology Department Warwick Hospital, Warwick, UK

,

Mei Gu

¹Clinical Science and Research Institute, Warwick University, Clifford Bridge Road, Coventry, UK

,

Peter Rose

²Warwick General Hospital Haematology Department Warwick Hospital, Warwick, UK

³University Hospital of Coventry, Clifford Bridge Road, Coventry, UK

,

Manu Vatish

¹Clinical Science and Research Institute, Warwick University, Clifford Bridge Road, Coventry, UK

³University Hospital of Coventry, Clifford Bridge Road, Coventry, UK

⁴Albert Einstein College of Medicine, Bronx, New York, USA

› Author Affiliations

Abstract

Full Text

References

References
1 Bajaj MS, Birktoft JJ, Steer SA. et al. Structure and biology of tissue factor pathway inhibitor. Thromb Haemost 2001; 86: 959-972.
2 Hackeng TM, Sere KM, Tans G. et al. Protein S stimulates inhibition of the tissue factor pathway by tissue factor pathway inhibitor. Proc Natl Acad Sci USA 2006; 103: 3106-3111.
3 Sandset PM, Bendz B. Tissue factor pathway inhibitor: clinical deficiency states. Thromb Haemost 1997; 78: 467-470.
4 Bai H, Ma D, Zhang Y. et al. Molecular design and characterization of recombinant long half-life mutants of human tissue factor pathway inhibiton. Thromb Haemost 2005; 93: 1055-1060.
5 Vinnars MT, Wijnaendts LC, Westgren M. et al. Severe preeclampsia with and without HELLP differ with regard to placental pathology. Hypertension 2008; 51: 1295-1299.
6 Kobayashi T, Tokunaga N, Sugimura M. et al. Coagulation/fibrinolysis disorder in patients with severe preeclampsia. Semin Thromb Hemost 1999; 25: 451-454.
7 Tanjung MT, Siddik HD, Hariman H. et al. Coagulation and fibrinolysis in preeclampsia and neonates. Clin Appl Thromb Hemost 2005; 11: 467-473.
8 Halligan A, Bonnar J, Sheppard B. et al. Haemostatic, fibrinolytic and endothelial variables in normal pregnancies and pre-eclampsia. Br J Obstet Gynaecol 1994; 101: 488-492.
9 Abdel Gader AM, Al-Mishari AA, Awadalla SA. et al. Total and free tissue factor pathway inhibitor in pregnancy hypertension. Int J Gynaecol Obstet 2006; 95: 248-253.
10 Davey DA, MacGillivray I. The classification and definition of the hypertensive disorders of pregnancy. Am J Obstet Gynecol 1988; 158: 892-898.
11 Unal ER, Robinson CJ, Johnson DD. et al. Second-trimester angiogenic factors as biomarkers for future-onset preeclampsia. Am J Obstet Gynecol 2007; 197: 211.
12 Polliotti BM, Fry AG, Saller DN. et al. Second-trimester maternal serum placental growth factor and vascular endothelial growth factor for predicting severe, early-onset preeclampsia. Obstet Gynecol 2003; 101: 1266-1274.
13 Powers RW, Roberts JM, Cooper KM. et al. Maternal serum soluble fms-like tyrosine kinase 1 concentrations are not increased in early pregnancy and decrease more slowly postpartum in women who develop preeclampsia. Am J Obstet Gynecol 2005; 193: 185-191.
14 Dusse LM, Carvalho MG, Getliffe K. et al. Total plasma tissue factor pathway inhibitor levels in preeclampsia. Clin Chim Acta 2008; 388: 230-232.